Key result
Pretransplant serum antibodies to peroxisomal-trans-2-enoyl-coA-reductase (PECR) were present in 75% of patients who eventually developed transplant glomerulopathy compared to 21% of wait-listed controls (P=0.01).
Why the study?
Do pretransplant serum antibodies to peroxisomal-trans-2-enoyl-coA-reductase (PECR) predict the development of transplant glomerulopathy in kidney transplant recipients?
Observational (n=72)
Yes
Do pretransplant serum antibodies to peroxisomal-trans-2-enoyl-coA-reductase (PECR) predict the development of transplant glomerulopathy in kidney transplant recipients?
Absolute Event Rate: 75% vs 21%
p-value: p=0.01
Pretransplant serum antibodies to the non-HLA antigen peroxisomal-trans-2-enoyl-coA-reductase (PECR) may serve as a biomarker predicting the development of transplant glomerulopathy in kidney transplant recipients.
Non-HLA autoantibody signatures may flag late allograft risk; leaves open causal role and need for targeted intervention trials.
Although T and B cell alloimmunity contribute to transplant injury, autoimmunity directed at kidney-expressed, non-HLA antigens may also participate. Because the specificity, prevalence, and importance of antibodies to non-HLA antigens in late allograft injury are poorly characterized, we used a protein microarray to compare antibody repertoires in pre- and post-transplant sera from several cohorts of patients with and without transplant glomerulopathy. Transplantation routinely induced changes in antibody repertoires, but we did not identify any de novo non-HLA antibodies common to patients with transplant glomerulopathy. The screening studies identified three reactivities present before transplantation that persisted after transplant and strongly associated with transplant glomerulopathy. ELISA confirmed that reactivity against peroxisomal-trans-2-enoyl-coA-reductase strongly associated with the development of transplant glomerulopathy in independent validation sets. In addition to providing insight into effects of transplantation on non-HLA antibody repertoires, these results suggest that pretransplant serum antibodies to peroxisomal-trans-2-enoyl-coA-reductase may predict prognosis in kidney transplantation.
No takes yet. Share an insight, caveat, or question.
Dinavahi et al. (2011) conducted an observational in Transplant Glomerulopathy (n=72). Pretransplant anti-PECR antibodies vs. Wait-listed transplant candidates was evaluated on Presence of pretransplant anti-PECR immunity (reactivity threshold >0.5) (p=0.01). Pretransplant serum antibodies to peroxisomal-trans-2-enoyl-coA-reductase (PECR) were present in 75% of patients who eventually developed transplant glomerulopathy compared to 21% of wait-listed controls (P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: